Deciphering cancer clues from blood
Menée à l'aide de cellules tumorales circulantes issues de patientes atteintes d'un cancer du sein et menée à l'aide d'un modèle murin, cette étude met en évidence un mécanisme par lequel la surexpression de certaines protéines ribosomales et de certaines protéines régulatrices de la traduction favorise le développement de métastases
Cancer is associated with considerable morbidity and mortality, and despite therapeutic advances, it still represents the second leading cause of death worldwide (1). As cancers grow, evolve, and spread, they shed circulating tumor cells (CTCs), as well as other tumor-associated cells and products, into the bloodstream. Capturing and analyzing CTCs or other tumor-associated cells and products from a patient's blood sample can provide insight into a particular cancer's biology, response to treatment, and/ or potential therapeutic targets (2). CTCs are heterogeneous; a pressing question concerns which CTCs represent those directly involved in metastasis, the major cause of cancer-related death. On page 1468 of this issue, Ebright et al. (3) identify genes in patient-derived CTCs encoding ribosomal proteins (RPs) that were associated with metastatic progression in mouse models, poor outcome in patients, and alterations in global translation. These findings could point to potential biomarkers or targets for future metastatic cancer therapies.
Science , commentaire, 2019